Parkinson’s disease: The basics Praveen Dayalu, MD Clinical Associate Professor Department of Neurology University of Michigan.

Slides:



Advertisements
Similar presentations
Pharmacological Management of Parkinson’s Disease
Advertisements

Parkinsons Disease Management in Primary Care. Introduction Progressive condition 1:500 whole population 1:50 of elderly 1:10 Nursing Home Residents.
MOTOR NEURON DISEASE The motor neuron diseases (or motor neuron diseases) (MND) are a group of neurological disorders that selectively affect motor neurons.
Sleep When a cup of warm milk is not enough K. Van Gundy, M.D. Associate Clinical Professor UCSF.
Non-motor Complications of Parkinson’s Disease and Management Valerie R. Suski, DO University of Pittsburgh Department of Neurology Pittsburgh Institute.
Evaluation of Movement Disorders
Diagnosis and Management of Parkinson’s Disease
Parkinson’s Disease (PD)
The PARticulars of Parkinson’s Disease
Parkinson’s Disease Dr Rachel Cary, Warwick Hospital.
Diagnosis and Treatment of Parkinson’s Disease Jeff Bronstein, MD, PhD Professor of Neurology at UCLA Director of the SW PADRECC Director of UCLA Movement.
Paul Short, Ph.D. The Parkinson’s Coach NEUROPSYCHOLOGY OF PARKINSON’S COMMUNICATION PROBLEMS.
Primary Symptoms It is important to note that not all patients experience the full range of symptoms; in fact, most do not. Rigidity is an increased tone.
Initial Diagnosis and Management of Parkinson’s Disease
Harald Bjorndalen Adapted from lecture by Dr Zoe Campbell (Medical SpR)
Parkinson’s Disease By Nik Sanyal.
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
Erica Partridge Parkinson’s Disease. Definition Aetiology PD vs Parkinsonism Symptoms and signs Differentials Investigations Management Prognosis.
Parkinson ’ s disease. Function Anatomy of Parkinson ’ s Disease.
Major Depressive Disorder Presenting Complaints
JP Parkinson’s Disease. Overview Idiopathic PD Clinically and pathologically distinct from other parkinsonian syndromes Degenerative disorder of the CNS.
Parkinson’s Disease By Devin Cornford
Chapter 30 Agents Used to Treat Parkinson’s Disease.
SYMPTOM CONTROL IN ADVANCED PARKINSON’S DISEASE Vicky Travers PDNSUHMBT April 2012.
Duodenal Levodopa Treatment in advanced Parkinson’s Disease
Drugs for Parkinon’s disease Parkinson's disease –progressive tremor –Bradykinesia and rigidity –degeneration of the dopaminergic nigrostriatal pathway.
The management of advanced Parkinson’s disease Dr J Paul Milnes Consultant Physician Airedale NHS Trust.
Parkinson’s Disease. Definition Parkinson's disease (PD) is an idiopathic, slowly progressive, neurodegenerative disorder whereby two or more of the following.
Treatment of Parkinson’s Disease Thomas L. Davis, M.D. Associate Professor of Neurology Vanderbilt School of Medicine.
Alzheimer’s Disease The most common cause of Dementia –Progressive Memory Loss Plus loss in one other area of cognition: Perception Attention Language/Symbols.
By Prof. Hanan Hagar Pharmacology unit Medical College.
Surgery for Parkinson’s Disease: Focus on Deep Brain Stimulation Ramón L Rodríguez, MD Director of Clinical Services University of Florida Movement Disorders.
Adult Medical-Surgical Nursing Neurology Module: Parkinson’s Disease.
Treatment of Parkinson Disease David Tran, 2013 Mercer University PharmD Candidate.
Mostly Parkinson’s disease but also few other movement disorders due to diseases of the basal ganglia.
Parkinson’s Disease Dr. Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.
A 57-year-old man with decreased stamina, decline in cognition, and tremor Joe Kovaz, M.D. Clinical Assistant Professor of Medicine.
Non Alzheimer's Dementias Elizabeth Landsverk, MD Geriatrician, ElderConsult Geriatric Medicine Adjunct Professor of Medicine, Stanford University.
A neurology primer. Idiopathic Parkinson Disease (also referred to as primary or classical Parkinson disease)  is a progressive neurodegenerative disorder.
second most common neurodegenerative disorder progressive loss of muscle control trembling of the limbs and head while at rest stiffness, slowness, and.
Parkinson's disease By Colby Allen. symptoms Mild to major tremors. Rigidity or joint stiffness Bradykinesia or slowness of movement Postural instability.
Drugs in parkinsonism ilos
PARKINSON’S DISEASE.
The Substantia Nigra THE BRAIN Symptoms differ from every person suffering from the disease. There are two types of symptoms, primary, secondary.
Parkinson’s Disease Angela Duncan June Why I Chose This Subject Common neurodegenerative disorder / in Scotland Expected increase.
Drugs Used for Parkinson’s Disease Chapter 15 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
ANTI- PARKINSONISM Dr: Samah Gaafar Al-shaygi.  Neurodegenerative diseases.  Dopamenergic neurones in substantia nigra.  Environmental* genetic factors.
Primary Symptoms It is important to note that not all patients experience the full range of symptoms; in fact, most do not. Rigidity is an increased tone.
Management of Parkinson’s disease (in the acute medical ward) C. M. James MD FRCP FAcadMEd Consultant Physician Withybush Hospital, Pembrokeshire.
ANTI-PARKINSONIAN DRUGS. Parkinsonism It is a common movement disorder that involves dysfunction in the basal ganglia and associated brain structures.
Parkinson’s Disease By: Taylor Hawkins, Ana McGhee, and Morgan Zander.
Parkinson's disease ♦ Is a neurodegenerative disorder ♦ Develops around age 50 * incidence rises with age * affects 1-2% of population > age 65 ♦ Higher.
Parkinson’s disease by Syed Baseeruddin Alvi (09).
Drugs Used for Parkinson’s Disease
Sleep and Parkinson’s Disease
Understanding Parkinsons Disease
Parkinson’s Disease Jose S. Santiago M.D..
MOVEMENT DISORDERS.
Interactive Session- Let’s Talk Orthostatic Hypotension
Drugs for Parkinson’s Disease
Parkinson's disease KRZYSZTOF NICPOŃ.
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
Parkinson's disease Parkinson's disease (PD) is the second-most common
The Approach to Tremor (with case examples) Praveen Dayalu MD Associate Professor Department of Neurology University of Michigan.
WHAT I NEED TO KNOW AS A PATIENT AND A CAREGIVER
Pharmacological Management of Parkinson’s Disease
Neurodegenerative diseases
Management in Primary Care
Parkinson’s Disease Definitions Disease features Pathology
HOW DOES EXPERIENCE AFFECT BEHAVIOUR AND MENTAL PROCESSES?
Presentation transcript:

Parkinson’s disease: The basics Praveen Dayalu, MD Clinical Associate Professor Department of Neurology University of Michigan

The basal ganglia

Basal ganglia Cerebellum

Parkinsonism comprises four cardinal motor features Bradykinesia (slow and small movements). Reduced blink, face expression, and gesturing. Soft voice. Difficulty getting out of chair, shuffling steps, reduced arm swing, freezing Tremor (usually resting) “pill rolling”, often involves thumb Rigidity (different from spasticity) Postural changes. Imbalance, falls; stooped flexed posture

Differential diagnosis of parkinsonism Parkinson disease (idiopathic or genetic) Parkinson-plus degenerations (dementia with Lewy bodies, progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy) Drug-induced parkinsonism (anti-dopaminergics) Rare but treatable in young people: Wilson disease and Dopa-responsive dystonia Other: “vascular” parkinsonism, brain trauma, CNS infection

Drug-Induced Parkinsonism Drugs that reduce dopamine transmission Antipsychotics / antiemetics: Risperidone, haloperidol, metoclopramide, promethazine, prochlorperazine, etc. Can be indistinguishable from PD Clozapine does not seem to cause it; quetiapine appears to have low rates Management: reduce or discontinue offending agent. Can take months to resolve!

Parkinson Disease (PD) Usually idiopathic Substantia nigra degeneration causes dopamine deficiency in striatum  motor symptoms Dopaminergic therapy relieves motor symptoms

Parkinson disease: Common early complaints Resting tremor Writing smaller; harder to do buttons Slowness, “weakness”, limb not working well Stiff or achy limb Stoop, shuffle-walk, “dragging” leg(s) Trouble getting out of chairs or turning in bed Low or soft voice Non-motor: anosmia, dream enactment, constipation, anxiety, depression, “passiveness”

PD: meds for motor symptoms L-dopa (with carbidopa) is most effective and usually best tolerated Dopamine agonists (ropinirole, pramipexole) Others have only modest benefits (MAO-B inhibitors, anticholinergics, amantadine)

Early PD: When to start meds? Drugs are symptomatic, not neuroprotective or neurotoxic Level of patient function is best guide Response to dopaminergic therapy (especially l-dopa) is the best available “test” for PD ** Remember the value of exercise! **

Which treatment to start? L-dopa most effective for motor symptoms in general (bradykinesia, tremor, gait changes) Family physicians can start levodopa !! Dopamine agonists cause more non-motor side effects, and are best avoided in patients above 70

Treatment pearls in early PD Fear not L-dopa. “Delaying L-dopa” is of no benefit long-term. Treat more for symptoms and function, and less for how the patient “looks”. Generics are fine. Allow adequate dose and time to work before concluding “failure” or “not PD”. Resting tremor may be medication refractory in some patients; don’t conclude “not PD”.

Levodopa Most effective overall for motor symptoms A fine option for initial therapy of PD By mid to late disease it is almost always needed Non-motor side effects include nausea, orthostasis, sleepiness, hallucinations; but not as much as other PD drugs Motor side effect: dyskinesias

Carbidopa/ levodopa dosing Commonest preparation is regular 25/100mg. Try 1 pill PO TID  1.5 pills TID  2 pills TID. With meals reduces nausea. 2 weeks between steps to appreciate effect. No response? At least 900mg/ d to say “not PD”. Some patients need QID or more frequent dosing (even Q3H in advanced disease). Typical daily l-dopa dose range: 300mg to 1500mg

Dopamine agonists (ropinirole, pramipexole, rotigotine) Can be monotherapy in early disease; need l-dopa in mid to late disease Can add to l-dopa to reduce OFF time Frequent side effects! Nausea, sleep attacks, hypotension, compulsive behaviors, LE edema  More prone than l-dopa to causing hallucinations and confusion. Caution in older or demented patients! 

Mid to late PD: a tricky business More motor complications including dyskinesias and ON-OFF fluctuations More drug-resistant motor symptoms (e.g. impaired balance with falls) More nonmotor symptoms (especially dementia and hallucinations) More medications, so more side effects Managing these complexities requires experience.

“Motor complications” as PD progresses Fluctuations. Medication wears off before next dose. OFF periods worse as disease progresses. Dyskinesias (usually at the peak of ON). Need larger and/or more frequent med doses, or combinations of drugs. Deep brain stimulation an option for some patients with medically refractory motor complications.

Some motor symptoms may not respond to med adjustments Postural instability and falls Freezing of gait Fatigue Dysarthria, dysphagia Some tremor (!)

Non-motor Symptoms Psychiatric (depression, anxiety) Autonomic (blood pressure, genitourinary, GI) Sleep (REM behavior disorder, insomnia, hypersomnia, sleep apnea) Fatigue Cognitive (psychosis, dementia) 20

Why non-motor symptoms? PD affects many parts of the nervous system Earliest involvement is in gut nerve plexus, lower brainstem, and olfactory bulb Pathology moves up the brainstem, also to serotonergic, noradrenergic, and cholinergic nuclei Non-motor symptoms (e.g. anosmia, constipation, dream enactment) often predate motor symptoms 21

Depression and anxiety It’s not just because of the stress of the diagnosis Motor symptoms and wearing off can interact with mood and anxiety levels Can misinterpret “poker face” as depression. Ask the patient! SSRI’s can work; avoid benzodiazepines 22

Depression and anxiety: other considerations Consider support services / psychotherapy for patients and caregivers Geriatric psychiatrists usually have better expertise in this population 23

Autonomic symptoms

Blood pressure dysregulation Causes orthostatic hypotension and supine hypertension Syncope can occur, sometimes with injury Worse with dopamine agonists and higher doses of L-dopa Lower extremity edema may also reflect vascular dysregulation 25

Recognizing orthostatic hypotension Not all have the classic lightheaded feeling Other clues: Abrupt falls Weakness, buckling, or shaking of legs or body Being dazed, confused, “goofy” Coat-hanger ache (neck and shoulders) 26

Managing orthostasis: first steps Reduce or stop antihypertensives, diuretics, other offenders (including some PD meds) Don’t over-treat isolated high BPs; 3 minute orthostatic BP gives a clearer picture Water, water, salt, and water Elevate head of bed to 30 degrees Compression stockings (groan) Teach first-aid/ bystander response 27

Managing orthostasis: prescription meds Fludrocortisone: retains body sodium (beware of hypokalemia) Midodrine: raises BP (beware supine hypertension) Droxidopa: turns to norepinephrine, raises BP (beware supine hypertension) 28

Urinary Symptoms Urgency, frequency, nocturia are very common Obstruction/ retention are less common Incontinence is uncommon early on Pathophysiology can be complex in any given patient Confounds: age, prostate issues, motor problems 29

Managing urinary symptoms Non-pharmacologic (timed voids, head of bed up for nocturia) Bladder antispasmodics: Oxybutynin, tolterodine, solifenacin, darifenacin: beware anticholinergic brain effects! Mirabegron– a novel adrenergic drug Might cause retention, especially in men Consider urology referral (can also address ED) 30

Constipation in PD May predate motor symptoms by years Slow transit or outlet obstruction Step 1: reasonable dietary fiber, water Step 2: mild osmotic laxatives (e.g., polyethylene glycol) For patients not responding to conservative measures, consider specialty referral 31

Sleep symptoms

REM sleep behavior disorder Typically in men, often years before motor symptoms Complex movements or fighting Usually early in the morning, varying frequency Patient or bed partner injury 33

REM sleep behavior disorder- treatment Treat any underlying OSA Make sleeping environment safer Melatonin mg qhs helps mild to moderate symptoms Clonazepam 0.25 – 1.0 mg qhs may be needed for more severe symptoms 34

Obstructive Sleep Apnea PD patients, even skinny ones, are more at risk for sleep-disordered breathing Maintain a high level of suspicion Can present with snoring, daytime somnolence, nighttime awakenings, nocturia, worsening dream enactment… 35

Insomnia Can be primary or secondary Address sleep hygiene Review med list Treat nighttime motor symptoms Think about OSA Treat psychiatric comorbidities Sedative/ hypnotics: melatonin, trazodone, mirtazapine, clonazepam (if RBD) 36

Hypersomnia PD increases sleep need for many patients Poor sleep at night (many causes) Think about OSA Review med list (make special note of dopamine agonists, anticholinergics, benzos, other sedatives) 37

Fatigue “Tired”, “Wiped out”, “No energy” Is it: Sleepiness? Wearing off? Motor? Mood? Isolated fatigue can be disabling No established treatment, though anti- depressants and stimulants have been tried Encourage light exercise, hobbies, etc We badly need better treatments for this 38

Hallucinations & Dementia in PD Complicate many longstanding PD cases Hallucinations are usually visual Main contributors are disease progression (brain pathologic changes), age, and meds Older patients much more at risk Marker for increased morbidity, mortality, and institutionalization

Hallucinations and dementia in PD Assess medical state; B12, TSH Simplify med regimen. Prioritize eliminating anticholinergics and dopamine agonists. Reduce L- dopa last. Rivastigmine (cholinesterase inhibitor) FDA approved in PD dementia Antipsychotics (off label, black-box warning!): quetiapine and clozapine least likely to worsen parkinsonism

Case Studies

A 66-year old woman on levodopa 100mg TID plus ropinirole 4 mg TID, has only mild wearing off between doses. She often falls asleep during work meetings, and blames her poor sleep: ‘I wake up a lot to pee. Can you prescribe me Detrol?” How might we improve her daytime alertness? How might we improve her nocturia? 42

A 69-year old woman with PD, CHF, HTN, and GERD is on 250mg TID of levodopa. Her prior hand tremor is much better controlled, and she usually walks around well, but her son notes increasing episodes of “severe whole body tremors”. What questions might clarify these episodes? Accordingly, what can we do about them? 43

An 81 y/o man with 10 years of Parkinson disease begins to see child soldiers peering in at the windows. He takes L-dopa, ropinirole, and alprazolam. What would you do?